BioAtla(BCAB) - 2025 Q2 - Earnings Call Presentation

BioAtla's CAB Platform and Pipeline - BioAtla is a clinical-stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)[9] - The CAB platform maximizes the therapeutic window and has broad applicability in solid tumors[10, 15] - BioAtla has proprietary technology with over 500 issued patents[10] BA3182 (CAB-EpCAM x CAB-CD3 TCE) - BA3182 is in Phase 1 dose escalation, with updated data expected in Q4 2025 and dose expansion planned for 1H 2026[10] - BA3182 targets EpCAM, which is expressed in a high percentage of various cancers, including 81% of breast cancers, 99% of prostate and pancreatic cancers, and 100% of colon cancers[37] - Preliminary data shows objective tumor size reductions in multiple tumor types, including a 13% reduction in intrahepatic cholangiocarcinoma[58, 59] - In a Phase 1 study with subcutaneous dosing (N=22), 91% of patients experienced any adverse events, but most were low-grade and manageable[56] Mecbotamab Vedotin (CAB-AXL-ADC) - Mecbotamab Vedotin (Mec-V) is being developed for mKRAS Non-Small Cell Lung Cancer (NSCLC)[63] - AXL is overexpressed in 70% to 85% of mKRAS NSCLC, driving aggressive tumor characteristics and resistance to therapies[72] - Mec-V at 1.8 mg/kg Q2W showed a 31% overall response rate (confirmed and unconfirmed) and a 67% one-year landmark overall survival in mKRAS NSCLC patients[74] Ozuriftamab Vedotin (CAB-ROR2-ADC) - Ozuriftamab Vedotin (Oz-V) is being developed for HPV+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)[88] - In SCCHN patients, Oz-V at 1.8 mg/kg Q2W showed a 45% overall response rate (confirmed and unconfirmed) and a median overall survival of 11.6 months in p16+ patients[104] - A meeting with the FDA is planned in Q3 2025 to confirm the proposed Phase 3 study design in 2L+ HPV+ OPSCC[10, 120] Evalstotug (CAB-CTLA-4) - Evalstotug is a next-generation adaptation of Ipilimumab, selectively active in the tumor microenvironment to reduce immune-mediated adverse events[122] - In a study of 17 patients treated with Evalstotug at 350 mg in combination with PD-1, the overall response rate was 44%[141] - In unresectable and/or metastatic cutaneous melanoma patients treated with Evalstotug (5 – 14.3 mg/kg) in combination with a PD-1 antibody, the overall response rate was 67% and the disease control rate was 92%[146, 163]